Table 1.
Clinical characteristics of the study population.
| Case | Age at first diagnosis | First diagnosis | CBC | LDH (U/L) (normal range) | Cytogenetics | Treatment | Outcome | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | 69 | HCL, CLL | WBC 20.8 (Ly 79%) | 100 (98–192) | Deletion of 7q31 | Rituximab | HCL in remission; stable CLL | 58 |
| Hgb 15.8 | ||||||||
| Plt 108 | ||||||||
| 2 | 49 | HCLa | WBC 11.1 (Ly 71%) | 563 (313–618) | Trisomy 12 | Cladribine | HCL relapse; development of CLL | 250 |
| Hgb 13.9 | ||||||||
| Plt 113 | ||||||||
| 3 | 47 | CLLb | WBC 3.1 | – | Deletion of 13q | Cladribine | HCL in remission; slow redevelopment of CLL with expectant management thereafter | 79 |
| Hgb 12.3 | ||||||||
| Plt 52 | ||||||||
| 4 | 43 | HCL, CLL | WBC 4.1 (Ly 34%) | 130 (98–192) | Trisomy 12, partial deletion of 5′ telomeric 14q32 locus | Cladribine | Worsening lymphadenopathy; lost to follow-up | 13 |
| Hgb 14.1 | ||||||||
| Plt 94 | ||||||||
| 5 | 79 | HCL, CLL | WBC 9.0 (Ly 68%) | – | None | Nonec | Transfer to an outside facility | 1 |
| Hgb 18.7 | ||||||||
| Plt 102 | ||||||||
CBC, complete blood count; HCL, hairy cell leukemia; CLL, chronic lymphocytic leukemia; WBCs, white blood cells (thousands of cells per microliter); Ly, lymphocytes; Hgb, hemoglobin (grams per deciliter); Hct, hematocrit; Plt, platelets (thousands of cells per microliter); SLL, small lymphocytic lymphoma.
aIn this patient, HCL relapsed after 7 years and was retreated with cladribine. The patient developed CLL 14 years after the initial diagnosis of HCL.
bIn this patient, CLL was diagnosed with HCL 10 months after initial diagnosis of CLL.
cThe patient was diagnosed with lung cancer and underwent therapy for lung cancer.